X-082-NAB

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameX-082-NAB

Drug Alias NameNATHMAB for systemic lupus erythematosus(XBiotech)X-082-NAB

ClassificationNatural product/ExtractBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionCytokine receptors antagonists

TargetsCytokine receptors

Therapy Area/IndicationsLupus Erythematosus, Systemic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesXbiotech Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesXbiotech Inc

Active IndicationsN/A

Inactive IndicationsLupus Erythematosus, Systemic

ATC CodeN/A